Published in Acta Physiol Scand on January 01, 2000
S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A (2002) 1.64
Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production. J Biol Chem (2009) 1.19
The subcellular compartmentalization of arginine metabolizing enzymes and their role in endothelial dysfunction. Front Immunol (2013) 0.87
Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells. Front Cell Neurosci (2014) 0.79
Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet (1992) 4.64
A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ (1999) 3.23
What is the optimal age for starting lipid lowering treatment? A mathematical model. BMJ (2000) 2.65
Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension (1995) 2.54
Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation (2000) 2.27
Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest (1992) 2.26
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res (2001) 2.02
Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J (1999) 2.00
Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens (1992) 1.77
Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res (1994) 1.74
Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res (1999) 1.69
Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol (1996) 1.68
Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients. Lancet (1982) 1.64
Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation (1997) 1.61
Measurement of nitrite and nitrate levels in plasma and urine--what does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens (1998) 1.51
Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation (2001) 1.49
Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension. Cardiovasc Res (1994) 1.43
Taking risks: primary prevention of cardiovascular events. N Z Med J (2001) 1.38
Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res (1993) 1.35
Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk. Kidney Int (2006) 1.30
Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol (1994) 1.28
Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int (1997) 1.28
Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol (2001) 1.28
Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke (1998) 1.26
Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke (2004) 1.25
Nitric oxide and cardiovascular control. Exp Physiol (1993) 1.21
Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics (2000) 1.20
Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int (1994) 1.20
Second messenger role for NO widens to nervous and immune systems. Trends Pharmacol Sci (1989) 1.17
Effect of inhibition of nitric oxide synthase on dynamic cerebral autoregulation in humans. Clin Sci (Lond) (2000) 1.12
Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet (2001) 1.12
Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res (1996) 1.11
Biochemical characterization of S-nitrosohemoglobin. Mechanisms underlying synthesis, no release, and biological activity. J Biol Chem (1999) 1.09
Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation (2000) 1.08
Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol (1995) 1.07
Lifetime risk of developing coronary heart disease. Lancet (1999) 1.04
Nitric oxide takes centre-stage with newly defined roles. Trends Pharmacol Sci (1992) 1.01
Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet (1993) 1.01
Effect of stress management on blood pressure in mild primary hypertension. BMJ (1993) 1.00
Drugs and the fetus. BMJ (1996) 1.00
Drug therapy for coronary heart disease: the Sheffield table. Lancet (1998) 0.99
Uptake and transport of Imposil by the glomerular mesangium in the mouse. Lab Invest (1977) 0.98
Local venous responses to endotoxin in humans. Circulation (1996) 0.98
Nitric oxide and vascular responses in Type I diabetes. Diabetologia (2000) 0.97
Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. J Am Coll Cardiol (2001) 0.97
Periodontal therapy: a novel non-drug-induced experimental model to study human inflammation. J Periodontal Res (2004) 0.96
Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol (1994) 0.96
Positive inotropic effects of NO donors in isolated guinea-pig and human cardiomyocytes independent of NO species and cyclic nucleotides. Cardiovasc Res (2000) 0.96
Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension (2001) 0.95
Nitric oxide and blood pressure: effects of nitric oxide deficiency. Curr Opin Nephrol Hypertens (1996) 0.95
Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J Pharmacol Exp Ther (1995) 0.95
Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant (1996) 0.95
Plasma nitrogen oxides and blood lactate concentrations in Ghanaian children with malaria. Trans R Soc Trop Med Hyg (1997) 0.93
Dilator actions of arginine in human peripheral vasculature. Clin Sci (Lond) (1991) 0.93
Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun (2003) 0.92
Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology. Br J Pharmacol (1999) 0.91
Differential effect of three cyclooxygenase inhibitors on human cerebral blood flow velocity and carbon dioxide reactivity. Stroke (1994) 0.91
Effects of cytokines on nitric oxide pathways in human vasculature. Curr Opin Nephrol Hypertens (1999) 0.89
Endothelium-dependent sensory NANC vasodilatation: involvement of ATP, CGRP and a possible NO store. Br J Pharmacol (1998) 0.89
Targeting of alanine: glyoxylate aminotransferase in normal individuals and its mistargeting in patients with primary hyperoxaluria type 1. Ann N Y Acad Sci (1996) 0.89
Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS. Cardiovasc Res (1999) 0.89
Nitric oxide in essential and renal hypertension. J Am Soc Nephrol (1994) 0.89
Endothelium-derived relaxing factor is an endogenous vasodilator in man. Br J Pharmacol (1989) 0.88
Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol (1997) 0.88
The effect of the nitric oxide donor glyceryl trinitrate on global and regional cerebral blood flow in man. J Neurol Sci (2000) 0.87
Biphasic response to acetylcholine in human veins in vivo: the role of the endothelium. Clin Sci (Lond) (1990) 0.87
Identification of microbial dimethylarginine dimethylaminohydrolase enzymes. Mol Microbiol (1999) 0.87
Procedures for the outpatient management of patients with deep venous thrombosis. Clin Lab Haematol (2005) 0.87
Effect of local inhibition of nitric oxide synthesis on forearm blood flow and dorsal hand vein size in patients with alcoholic cirrhosis. Clin Sci (Lond) (1994) 0.87
Flow associated or flow mediated dilatation? More than just semantics. Heart (1997) 0.87
Changes in endothelium-dependent vasodilatation and alpha-adrenergic responses in resistance vessels during the menstrual cycle in healthy women. J Clin Endocrinol Metab (2001) 0.87
Physiological importance of nitric oxide. BMJ (1991) 0.86
Why do doctors not report adverse drug reactions? Neth J Med (1985) 0.86
Nitric oxide 9 years on. J R Soc Med (1996) 0.85
The effect of the nitric oxide synthase inhibitor L-NMMA on basal CBF and vasoneuronal coupling in man: a PET study. J Cereb Blood Flow Metab (1999) 0.85
Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? Clin Sci (Lond) (1995) 0.85
Vasodilatation to arachidonic acid in humans. An insight into endogenous prostanoids and effects of aspirin. Circulation (1995) 0.85
Tyrosine nitration in blood vessels occurs with increasing nitric oxide concentration. Br J Pharmacol (1999) 0.84
Endogenous inhibitors of nitric oxide synthesis: how important are they? Exp Nephrol (1998) 0.84
Evidence for functional responses to sensory nerve stimulation of rat small mesenteric veins. J Pharmacol Exp Ther (1997) 0.83
Interaction between sympathetic and sensory nerves in rat small arteries: involvement of nitric oxide. Am J Physiol (1996) 0.83
Prospective study of mortality associated with chronic lung disease and smoking in Papua New Guinea. Int J Epidemiol (1988) 0.82
Effects of diabetic control and biosynthetic human insulin on blood rheology in established diabetics. Diabetes Res (1984) 0.81
The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteers. Br J Clin Pharmacol (1989) 0.81
Nitric oxide: an endogenous gas. Br J Anaesth (1995) 0.81
Impaired vascular sensitivity to nitric oxide in the coronary microvasculature after endotoxaemia. Br J Pharmacol (2000) 0.80
Functional effects of econazole on inducible nitric oxide synthase: production of a calmodulin-dependent enzyme. Br J Pharmacol (1996) 0.80
ADMA regulates angiogenesis: genetic and metabolic evidence. Vasc Med (2005) 0.80
Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens (1993) 0.80
The effect of malnutrition on cardiovascular mortality in dialysis patients: is L-arginine the answer? Nephrol Dial Transplant (1994) 0.79
Role of thromboxane A2 in the vasoconstrictor response to endothelin-1, angiotensin II and 5-hydroxytryptamine in human placental vessels. Placenta (1995) 0.79
Systemic vascular adaptation to increases in blood volume: the role of the blood-vessel wall. Nephrol Dial Transplant (1996) 0.79
On the regulation of tone in vasa vasorum. Cardiovasc Res (1999) 0.79
NO in the cardiovascular system. Cardiovasc Res (1999) 0.79
Cholinergic contraction is altered in nNOS knockouts. Cooperative modulation of neural bronchoconstriction by nNOS and COX. Am J Respir Crit Care Med (1999) 0.79
Asthma and chronic airflow limitation in the highlands of Papua New Guinea: low prevalence of asthma in the Asaro Valley. Eur Respir J (1989) 0.78
Nitric oxide: not just a negative inotrope. Eur J Heart Fail (2001) 0.78